Nav: Home

Intermountain healthcare honored by the CDC for protocols to reduce blood clots

March 31, 2016

Intermountain Healthcare is one of eight health systems and hospitals nationwide that were recognized Tuesday by the U.S. Centers for Disease Control and Prevention for implementing protocols that have helped to reduce the rate of venous thromboembolism (VTE), or blood clots, among hospital patients.

Intermountain was awarded the CDC's HA-VTE Prevention Champion award, which honors the ongoing research and best-practice protocols within Intermountain to prevent hospitalized patients from developing blood clots.

Besides Intermountain, other national VTE champions include: Mayo Clinic, Northwestern Memorial Hospital in Chicago, and Johns Hopkins Hospital in Baltimore.

The purpose of the CDC's recognition program is to encourage other hospitals and health systems to adopt best practices created by the eight VTE champions. The CDC estimates that up to 900,000 venous thromboembolism events occur in the U.S. each year, resulting in as many as 100,000 premature deaths.

VTE-associated healthcare costs may also be as high as $10 billion a year. Without appropriate prevention, it's estimated that as many as 15 percent of hospitalized medical patients will develop hospital-acquired blood clots.

National guidelines recommend VTE-risk assessment protocols for hospitalized medical patients, but they aren't uniformly followed across the nation. Therefore, the CDC began the Healthcare-Associated Venous Thromboembolism Prevention Champion program to recognize health care systems and hospitals that are working to reduce VTE rates and encourage other hospitals to adopt their protocols and best practices.

"Healthcare-associated VTE is a serious and growing public health problem," says Thomas Frieden, MD, MPH, director of the CDC. "These challenge winners saved lives by implementing innovative VTE prevention strategies in their institutions. We can all learn from their ideas and work together to protect patients from developing deadly blood clots."

As part of the protocol, Intermountain Healthcare hospitals utilize an electronic tool that resides in the electronic patient record, which scans the medical record of hospitalized patients daily.

"If a patient is found to be at risk for blood clots, and is not receiving an appropriate medicine to prevent clots, the hospitalist caring for the patient is sent a secure text message alerting them to assure best care is being given," said Scott Woller, MD, co-director of Intermountain Medical Center's Thrombosis Clinic, and principle investigator of the project.

The protocol was launched at Intermountain Medical Center and LDS Hospital, and then implemented at Intermountain's Park City Medical Center, Utah Valley, McKay-Dee, and Riverton hospitals. The initiative is expected to expand across the entire 22-hospital Intermountain Healthcare system.

As part of the initiative, Intermountain hospitalist physicians receive a monthly report on their response to the alerts, their performance, and patient outcomes. Intermountain partnered with Twine Clinical Consulting, LLC, and Medical Impact Ventures, LLC, to create the proprietary audit-and-assessment tools used in the initiative.

"The expertise of Twine Clinical was invaluable in generating the monthly feedback to the individual physicians in an easy-to-use dashboard format that gives them real-time data regarding their personal performance and the resolution of blood clots among patients under their care," Dr. Woller said.

"This groundbreaking work by Dr. Woller and his colleagues shows why Intermountain Healthcare is so effective in improving care and reducing costs," said Mark Ott, MD, chief medical director of Intermountain's Salt Lake Valley hospitals. "By using data to track the care we provide and increase our adherence to proven care processes our patients get better outcomes and avoid the complications that threaten their safety and increase their costs."

The CDC HA-VTE Champions' work will be posted on the CDC's website, shared by the U.S. Agency for Healthcare Research and Quality, and displayed at the 2016 Thrombosis and Hemostasis Summit of North America in April in Chicago.

The Champions range from a small community hospital to some of the country's largest health systems, and they represent both rural and urban areas. Together they cared for more than 450,000 patients admitted to hospitals across the United States in 2014.

They were able to improve VTE prevention within their institutions and organizations by implementing innovative, effective and sustainable VTE prevention strategies, including:
    - Engaging teams of different healthcare experts to support and promote prevention activities.

    - Informing patients and providers about the need for and benefits of VTE prevention.

    - Using technology (such as electronic risk assessment and clinical decision support tools and alerts) to ensure that all patients are assessed for their risk for VTE and bleeding.

    - Providing real-time feedback, scorecards and dashboards for providers and organizations to monitor performance and identify areas for improvement.

For more information and to see profiles of the winners and their initiatives, please visit

Intermountain Medical Center

Related Blood Clots Articles:

Cellular senescence is associated with age-related blood clots
Cells that become senescent irrevocably stop dividing under stress, spewing out a mix of inflammatory proteins that lead to chronic inflammation as more and more of the cells accumulate over time.
New guidance on potentially fatal blood clots published today
The European Society of Cardiology (ESC) Guidelines on acute pulmonary embolism are published online today in European Heart Journal, and on the ESC website.
One in five haematological cancer patients suffer blood clots or bleeding
In the years following haematological cancer, one in five survivors suffer a blood clot or bleeding which requires hospital treatment.
Targeting inflammation to better understand dangerous blood clots
Forty percent of people who develop venous thromboembolism don't know what caused it.
Impeding white blood cells in antiphospholipid syndrome reduced blood clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.
Research unlocks biomechanical mystery behind deadly blood clots
Researchers at the University of Sydney have used biomechanical engineering techniques to unlock the mystery surrounding the mechanical forces that influence blood clotting.
HRT tablets associated with increased risk of blood clots
Hormone replacement therapy (HRT) tablets are associated with a higher risk of rare but serious blood clots (known as venous thromboembolism or VTE), finds a large study in The BMJ today.
HRT tablets increase risk of blood clots in women
Women who use certain types of hormone replacement therapy (HRT) are at a higher risk of developing potentially life-threatening blood clots, new research has confirmed.
How and why blood clots shrink
In an article published in Nature Communications, researchers at the University of California, Riverside and the University of Pennsylvania School of Medicine used high-powered microscopy and rheometry -- the measurement of how materials become deformed in response to applied force -- to view the blood clotting process in real time and at the cellular level.
Can height increase risk for blood clots in veins?
Risk of blood clots in the veins was associated with height, with the lowest risk in participants who were five feet tall or shorter.
More Blood Clots News and Blood Clots Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.